These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23892411)

  • 1. Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.
    Cai X; Cao W; Ding H; Liu T; Zhou X; Wang M; Zhong M; Zhao Z; Xu Q; Wang L
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1579-89. PubMed ID: 23892411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
    World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Hirata K; Nagata N; Kato T; Okuyama Y; Andoh H; Takahashi K; Oba K; Sakamoto J; Hazama S; Mishima H
    Anticancer Res; 2014 Jan; 34(1):195-201. PubMed ID: 24403462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
    Cai X; Tian C; Wang L; Zhuang R; Zhang X; Guo Y; Lu H; Wang H; Li X; Gao J; Li Q; Wang C
    Cancer Biol Ther; 2017 Mar; 18(3):186-193. PubMed ID: 28278081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
    Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
    Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Xu C; Tang X; Qu Y; Keyoumu S; Zhou N; Tang Y
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):119-30. PubMed ID: 27220761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
    Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
    World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
    Hirose K; Yamashita K; Takada H; Kaneda N; Fukami K; Maruo E; Kitamura M; Hasegawa J; Maeda Y
    Int J Clin Oncol; 2014 Apr; 19(2):397-402. PubMed ID: 23605141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
    Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
    J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
    Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
    Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism.
    Hazama S; Nagashima A; Kondo H; Yoshida S; Shimizu R; Araki A; Yoshino S; Okayama N; Hinoda Y; Oka M
    Cancer Sci; 2010 Mar; 101(3):722-7. PubMed ID: 20028383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic changes of irinotecan by intestinal alkalinization in an advanced colorectal cancer patient.
    Hamada A; Aoki A; Terazaki H; Ito K; Yokoo K; Sasaki Y; Saito H
    Ther Drug Monit; 2005 Aug; 27(4):536-8. PubMed ID: 16044114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
    de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
    Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals.
    Liu JY; Qu K; Sferruzza AD; Bender RA
    Anticancer Drugs; 2007 Jul; 18(6):693-6. PubMed ID: 17762398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.